Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease
Gastroenterology2016Vol. 150(7), pp. 1590–1598
Citations Over TimeTop 1% of 2016 papers
Paul J. Pockros, K. Rajender Reddy, Parvez Mantry, E. Cohen, Michael Bennett, Mark Sulkowski, David Bernstein, Daniel E. Cohen, Nancy S. Shulman, Deli Wang, Amit Khatri, Manal Abunimeh, Thomas Podsadecki, Eric Lawitz
Abstract
In a clinical trial, the combination of ombitasvir, paritaprevir, and ritonavir, administered with dasabuvir, led to an SVR12 in 90% of patients with HCV genotype 1 infection and stage 4 or 5 CKD. The regimen is well tolerated, though RBV use may require a reduction or interruption to manage anemia. ClinicalTrials.gov ID NCT02207088.
Related Papers
- → Distribution of hepatitis C virus genotypes in Jeju Island(2008)10 cited
- [Analysis on genotype distribution and mutation of major hydroponic region of hepatitis B virus in Liaoning].(2015)
- Analysis of hepatitis B virus genotype,virus loads,pre-core/core promoter region of nucleotide sequence in lamivudine-resistant hepatitis B virus in vivo(2007)
- Relationship between Genotypes and Mutation of Hepatitis B Virus in 88 Hepatitis B Patients in Shanghai(2013)
- Distribution of hepatitis B virus genotypes in intrauterine transmission and characteristics in Taiyuan(2004)